Drug Profile
Pirtobrutinib - Loxo Oncology
Alternative Names: Jaypirca; LOXO-305; LY 3527727; RXC-005Latest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Redx Pharma
- Developer Eli Lilly and Company; Loxo Oncology
- Class Amides; Amines; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Phase II Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Phase I/II Marginal zone B-cell lymphoma
- Phase I Haematological malignancies
Most Recent Events
- 27 Mar 2024 Loxo Oncology and Eli Lilly and Company withdrew a phase II trial prior to enrollment, in Multiple sclerosis (In adults) in USA and Puerto Rico (PO), due to a sponsor decision (NCT06104683)
- 11 Dec 2023 Efficacy and adverse events data from a phase I/II BRUIN trial in Chronic lymphocytic leukaemia and Non-Hodgkin lymphoma released by Eli Lilly and Company
- 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Non-Hodgkin's lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)